Learn More
The updated results of the precise measurements of the processes e + S performed by the CMD-2 collaboration are presented. The update appeared necessary due an overestimate of the integrated luminosity in previous analyses. 1 deceased-e + e τ , µ e, H H τ , µ e, a) b) Fig. 1. Diagrams of the vacuum polarization contribution to the e + e − → e + e − cross(More)
Positron emission mammography (PEM) provides images of biochemical activity in the breast with spatial resolution matching individual ducts (1.5 mm full-width at half-maximum). This spatial resolution, supported by count efficiency that results in high signal-to-noise ratio, allows confident visualization of intraductal as well as invasive breast cancers.(More)
The principle of magnetic drug targeting, wherein therapy is attached to magnetically responsive carriers and magnetic fields are used to direct that therapy to disease locations, has been around for nearly two decades. Yet our ability to safely and effectively direct therapy to where it needs to go, for instance to deep tissue targets, remains limited. To(More)
BACKGROUND Evaluation of high-risk mammograms represents an enormous clinical challenge. Functional breast imaging coupled with mammography (positron emission mammography [PEM]) could improve imaging of such lesions. A prospective study was performed using PEM in women scheduled for stereotactic breast biopsy. METHODS Patients were recruited from the(More)
PURPOSE A time-varying magnetic field can cause unpleasant peripheral nerve stimulation (PNS) when the maximum excursion of the magnetic field (ΔB) is above a frequency-dependent threshold level [P. Mansfield and P. R. Harvey, Magn. Reson. Med. 29, 746-758 (1993)]. Clinical and research magnetic resonance imaging (MRI) gradient systems have been designed to(More)
The ability to use magnets external to the body to focus therapy to deep tissue targets has remained an elusive goal in magnetic drug targeting. Researchers have hitherto been able to manipulate magnetic nanotherapeutics in vivo with nearby magnets but have remained unable to focus these therapies to targets deep within the body using magnets external to(More)
Introduction In clinical MRI scanners, dB/dt is limited to typically below 50 T/s (for a ramp duration of 0.2 ms), due to unpleasant peripheral nerve stimulation (" PNS ") caused by electric fields induced in the body [1]. Prior clinical trials involving magnetic gradients, with rise-and fall-times as short as 50 µs (with dB/dt rates as high as 400 T/s(More)
The principle of magnetic drug targeting, wherein therapy is attached to magnetically responsive carriers and magnetic fields are used to direct that therapy to disease locations, has been around for nearly two decades. Yet our ability to safely and effectively direct therapy to where it needs to go, for instance to deep tissue targets, remains limited. To(More)